ArticleFrontiers in immunology2023

Reinforcement of cell-mediated immunity driven by tumor-associated Epstein-Barr virus (EBV)-specific T cells during targeted B-cell therapy with rituximab.

Sabine Tischer-Zimmermann et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.